Aro Biotherapeutics

PHILADELPHIA, PA — Aro Biotherapeutics reported interim data from a Phase 1b study of ABX1100, an investigational therapy for late-onset Pompe disease, showing the drug was generally well tolerated and …

PHILADELPHIA, PA — Aro Biotherapeutics said it will present interim clinical data next month from its ongoing Phase 1b trial of ABX1100, an experimental therapy aimed at treating late-onset Pompe …

PHILADELPHIA, PA — Aro Biotherapeutics announced it has completed enrollment in its Phase 1b clinical trial of ABX1100, an investigational therapy for late-onset Pompe disease (LOPD). The study is designed …